Celldex Therapeutics Inc
CLDX
Detailliertes Diagramm anzeigen
24.370USD
+1.700+7.50%
Handelsschluss 11/11, 16:00（ET）Kurse um 15 Minuten verzögert
1.62BMarktkapitalisierung
VerlustKGV TTM
Intraday
1m
30m
1h
D
W
M
D
Heute
+7.50%
5 Tage
+2.18%
1 Monat
-8.97%
6 Monate
+32.95%
Seit Jahresbeginn
-3.56%
1 Jahr
-7.02%
Detailliertes Diagramm anzeigen
TradingKey Aktienbewertung von Celldex Therapeutics Inc
Währung: USD Aktualisiert: 2025-11-11Wichtige Einblicke
Die Fundamentaldaten des Unternehmens sind relativ gesund. Seine Bewertung wird als angemessen bewertet angesehen,und die institutionelle Anerkennung ist sehr hoch. In den letzten 30 Tagen haben mehrere Analysten die Aktie mit einer Kaufen bewertet. Trotz einer schwachen Aktienmarktperformance zeigt das Unternehmen starke technische Indikatoren. Der Aktienkurs bewegt sich seitwärts zwischen den Unterstützungs- und Widerstandsniveaus, was ihn für schwankungsorientiertes Trading geeignet macht.
Celldex Therapeutics Inc Bewertung
Widerstand & Unterstützung
Keine Daten
Radar Chart
Aktueller Preis
Vorher
Analysten-Ziel
Basierend auf insgesamt
16
Analysten
Kaufen
Aktuelles Rating
53.143
Kursziel
+134.42%
Aufwärtspotenzial
Hinweis: Analystenbewertungen und Kursziele werden von LSEG ausschließlich zu Informationszwecken bereitgestellt und stellen keine Anlageberatung dar.
Celldex Therapeutics Inc Highlights
HöhepunkteRisiko
Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its Barzolvolimab, a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis and Eosinophilic Esophagitis. The Company’s bispecific antibody platform to support pipeline expansion with additional candidates for inflammatory diseases and oncology. Bispecific Platform includes CDX-585. CDX-585 combines its highly active PD-1 blockade and anti-ILT4 blockade to overcome immunosuppressive signals in T cells and myeloid cells, respectively.
performance_growth_high
performance_growth_high_desc%!(EXTRA string=197.84%)
performance_growth_period
performance_growth_period_desc%!(EXTRA string=7.02M)
high_profit_growth
high_profit_growth_desc%!(EXTRA string=7.02M)
valuation_overestimated
valuation_overestimated_desc%!(EXTRA string=PE, string=-7.20)
institutional_decreasing_position
institutional_decreasing_position_desc%!(EXTRA string=73.66M, string=16.40%)
institutional_hold%!(EXTRA string=Steven Cohen)
institutional_hold_desc%!(EXTRA string=Steven Cohen, string=2.80M)
activity_increase
activity_increase_desc%!(EXTRA string=0.51)
Celldex Therapeutics Inc Nachrichten
Bald gibt es mehr Neuigkeiten, bleiben Sie dran...
Finanzindikatoren
EPS
Keine Daten
Gesamteinnahmen
Keine Daten
Celldex Therapeutics Inc Informationen
Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its Barzolvolimab, a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis and Eosinophilic Esophagitis. The Company’s bispecific antibody platform to support pipeline expansion with additional candidates for inflammatory diseases and oncology. Bispecific Platform includes CDX-585. CDX-585 combines its highly active PD-1 blockade and anti-ILT4 blockade to overcome immunosuppressive signals in T cells and myeloid cells, respectively.
BörsenkürzelCLDX
UnternehmenCelldex Therapeutics Inc
CEOMr. Anthony S. Marucci
Websitehttps://celldex.com/
Verwandte Finanzinstrumente
+2.27%
+2.88%
+2.95%
+1.84%
+2.59%
+4.84%
+4.57%
+6.99%
+3.73%
+4.59%
+2.03%
+1.90%
-0.34%
+3.09%
+2.22%
+2.93%
0.00%
+3.03%
+2.32%
+2.28%Beliebte Symbole
